Patient Portal

Joel Picus, MD

Professor, Medicine
Division of Oncology - Medical Oncology
Section, Medical and Molecular Oncology

Specialty Areas

Oncology
Hematology
Gastrointestinal Oncology
Hepatobiliary Cancer
Colon and Rectal Cancer
Genitourinary Oncology
Pancreatic Cancer

Board Certifications

Hematology
Internal Medicine
Oncology

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Diagnosis of tumors, renal cell carcinoma, RCC, pancreatic cancer, pancreas, cholangiocarcinoma, prostate cancer, colon cancer, bladder cancer, rectal carcinoma, immunotherapy, chemotherapy, GI cancer, GU cancer

  • Location(s)
  • Education
  • Publication & Research

Location(s)

Location(s)

Center for Advanced Medicine
Siteman Cancer Center

4921 Parkview Place
St. Louis, MO 63110

Suite: B
Floor: 7
Office Phone: 314-747-9281
Fax: 314-362-7086

Siteman Cancer Center - South County

5225 MidAmerica Plaza
St. Louis, MO 63129

Office Phone: 314 747 1171

Education

Education

Fellowship: Hematology and Oncology, Cancer Research Institute, University of California, San Francisco, CA 1991
Residency: Internal Medicine, Duke University Medical Center 1987
Medical Degree: Harvard Medical School, Boston, MA 1984
B.S.: Electrical Engineering, University of Illinois, Urbana, IL 1979
B.A.: Biology, University of Illinois, Urbana, IL 1979

Publication & Research

Publication & Research

Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.
George DJ, Hessel C, Halabi S, Michaelson MD, Hahn O, Walsh M, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, Morris MJ, Choueiri TK
Oncologist. 2019 Nov; 24(11)1497-1501. doi: 10.1634/theoncologist.2019-0316.

PMID:
    31399500
    [PubMed - in process]
Related citations


Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer.
Amin M, Desai M, Trinkaus K, Brown A, Wang-Gillam A, Tan B, Picus J, Sorscher S, Highkin M, Lears K, Lockhart AC
J Gastrointest Oncol. 2019 Jun; 10(3)412-420. doi: 10.21037/jgo.2019.02.01.

PMID:
    31183190
    [PubMed]
Related citations


Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer.
Slovin S, Hussain S, Saad F, Garcia J, Picus J, Ferraldeschi R, Crespo M, Flohr P, Riisnaes R, Lin C, Keer H, Oganesian A, Workman P, de Bono J
Clin Cancer Res. 2019 Aug 1; 25(15)4624-4633. doi: 10.1158/1078-0432.CCR-18-3212.

PMID:
    31113841
    [PubMed - in process]
Related citations


A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database.
Fischer-Valuck BW, Michalski JM, Contreras JA, Brenneman R, Christodouleas JP, Abraham CD, Kim EH, Arora VK, Bullock AD, Carmona R, Figenshau RS, Grubb R 3rd, Knoche EM, Pachynski RK, Picus J, Roth BJ, Sargos P, Andriole GL, Gay HA, Baumann BC
Clin Transl Radiat Oncol. 2019 Feb; 1538-41. doi: 10.1016/j.ctro.2018.12.001.

PMID:
    30656221
    [PubMed]
Related citations


Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.
Grivas P, Mortazavi A, Picus J, Hahn NM, Milowsky MI, Hart LL, Alva A, Bellmunt J, Pal SK, Bambury RM, O'Donnell PH, Gupta S, Guancial EA, Sonpavde GP, Faltaos D, Potvin D, Christensen JG, Chao RC, Rosenberg JE
Cancer. 2019 Feb 15; 125(4)533-540. doi: 10.1002/cncr.31817.

PMID:
    30570744
    [PubMed - in process]
Related citations


Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125].
Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ
Eur J Cancer. 2018 Nov; 103287. doi: 10.1016/j.ejca.2018.09.022.

PMID:
    30270112
    [PubMed]
Related citations


Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2).
Rosenberg JE, Hahn NM, Regan MM, Werner L, Alva A, George S, Picus J, Alter R, Balar A, Hoffman-Censits J, Grivas P, Lauer R, Guancial EA, Hoimes C, Sonpavde G, Albany C, Stein MN, Breen T, Jacobs C, Anderson K, Bellmunt J, Lalani AA, Pal S, Choueiri TK
Br J Cancer. 2018 May; 118(11)1434-1441. doi: 10.1038/s41416-018-0087-9.

PMID:
    29765151
    [PubMed - indexed for MEDLINE]
Related citations


Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.
Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ
Eur J Cancer. 2018 May; 94115-125. doi: 10.1016/j.ejca.2018.02.012.

PMID:
    29550566
    [PubMed - indexed for MEDLINE]
Related citations


Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
Gravis G, Boher JM, Chen YH, Liu G, Fizazi K, Carducci MA, Oudard S, Joly F, Jarrard DM, Soulie M, Eisenberger MJ, Habibian M, Dreicer R, Garcia JA, Hussain MHM, Kohli M, Vogelzang NJ, Picus J, DiPaola R, Sweeney C
Eur Urol. 2018 Jun; 73(6)847-855. doi: 10.1016/j.eururo.2018.02.001.

PMID:
    29475737
    [PubMed - indexed for MEDLINE]
Related citations


Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.
Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ
J Clin Oncol. 2018 Apr 10; 36(11)1080-1087. doi: 10.1200/JCO.2017.75.3657.

PMID:
    29384722
    [PubMed - indexed for MEDLINE]
Related citations


Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.
Harshman LC, Chen YH, Liu G, Carducci MA, Jarrard D, Dreicer R, Hahn N, Garcia JA, Hussain M, Shevrin D, Eisenberger M, Kohli M, Plimack ER, Cooney M, Vogelzang NJ, Picus J, Dipaola R, Sweeney CJ, ECOG-ACRIN 3805 Investigators.
J Clin Oncol. 2018 Feb 1; 36(4)376-382. doi: 10.1200/JCO.2017.75.3921.

PMID:
    29261442
    [PubMed - indexed for MEDLINE]
Related citations


Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, Feldman DR, Olencki T, Picus J, Small EJ, Dakhil S, George DJ, Morris MJ
J Clin Oncol. 2017 Feb 20; 35(6)591-597. doi: 10.1200/JCO.2016.70.7398.

PMID:
    28199818
    [PubMed - indexed for MEDLINE]
Related citations


Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study.
Azad NS, El-Khoueiry A, Yin J, Oberg AL, Flynn P, Adkins D, Sharma A, Weisenberger DJ, Brown T, Medvari P, Jones PA, Easwaran H, Kamel I, Bahary N, Kim G, Picus J, Pitot HC, Erlichman C, Donehower R, Shen H, Laird PW, Piekarz R, Baylin S, Ahuja N
Oncotarget. 2017 May 23; 8(21)35326-35338. doi: 10.18632/oncotarget.15108.

PMID:
    28186961
    [PubMed - indexed for MEDLINE]
Related citations


Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T, SUSTAIN-6 Investigators.
N Engl J Med. 2016 Nov 10; 375(19)1834-1844.

PMID:
    27633186
    [PubMed - indexed for MEDLINE]
Related citations


Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study.
Adra N, Albany C, Brames MJ, Case-Eads S, Johnson CS, Liu Z, Fausel CA, Breen T, Hanna NH, Hauke RJ, Picus J, Einhorn LH
Support Care Cancer. 2016 Jul; 24(7)2837-42. doi: 10.1007/s00520-016-3100-y.

PMID:
    26838019
    [PubMed - indexed for MEDLINE]
Related citations


Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.
Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, Ryan CW, Protheroe A, Lusk CM, Oberg S, George DJ
Lancet Oncol. 2016 Mar; 17(3)378-88. doi: 10.1016/S1470-2045(15)00515-X.

PMID:
    26794930
    [PubMed - indexed for MEDLINE]
Related citations


Phase 1 Evaluation of [(64)Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors.
Lockhart AC, Liu Y, Dehdashti F, Laforest R, Picus J, Frye J, Trull L, Belanger S, Desai M, Mahmood S, Mendell J, Welch MJ, Siegel BA
Mol Imaging Biol. 2016 Jun; 18(3)446-53. doi: 10.1007/s11307-015-0912-y.

PMID:
    26567113
    [PubMed - indexed for MEDLINE]
Related citations


Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS
N Engl J Med. 2015 Aug 20; 373(8)737-46. doi: 10.1056/NEJMoa1503747.

PMID:
    26244877
    [PubMed - indexed for MEDLINE]
Related citations


A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma.
Cho M, Wang-Gillam A, Myerson R, Gao F, Strasberg S, Picus J, Sorscher S, Fournier C, Nagaraj G, Parikh P, Suresh R, Linehan D, Tan BR
HPB (Oxford). 2015 Jul; 17(7)587-93. doi: 10.1111/hpb.12413.

PMID:
    25800066
    [PubMed - indexed for MEDLINE]
Related citations


Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study.
Merchan JR, Qin R, Pitot H, Picus J, Liu G, Fitch T, Maples WJ, Flynn PJ, Fruth BF, Erlichman C
Cancer Chemother Pharmacol. 2015 Mar; 75(3)485-93. doi: 10.1007/s00280-014-2668-5.

PMID:
    25556030
    [PubMed - indexed for MEDLINE]
Related citations